TEL
AVIV, Israel, June 9, 2022
/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB),
(Chemomab), a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, today announced
that the company will participate in a number of investor and
scientific conferences in June
2022.
JMP Securities Life Sciences Conference:
Date:
Thursday, June 16, 2022
Venue:
Lotte Palace Hotel, New York, NY
USA
Format:
In-person live and webcast presentation; One-on-one meetings on
June 16
Time:
11:00 a.m. ET
Link: https://wsw.com/webcast/jmp54/cmmb/1657584
Information:
https://jmp-ls.ljfevents-rsvp.com/registration/
A replay of the webcast will be available at the Investor
section of Chemomab's website for at least 30 days.
The Extracellular Matrix Pharmacology Congress
Date:
June 23-25, 2022
Venue: Tivoli Congress Center, Copenhagen, Denmark
Format:
Poster presentation: CCL24 Inhibition by CM-101 Attenuates
Extracellular Matrix and Fibrotic Biomarkers in Both Patients
and Experimental Murine Models, Abstract ID:155
Time:
Poster Session 1, June 23 from
13:00 - 14:15 CET
Presenter: Udi
Gluschnaider, PhD, Chemomab Project Lead
Information: ECM Congress
(ecm-congress.org)
A copy of the poster will be available at the R&D section of
Chemomab's website starting on June 23,
2022.
EASL: The International Liver Congress™ 2022
Date:
June 22-26, 2022
Venue:
ExCeL London, London, UK, and
virtual
Format:
Oral poster presentation: Combination of whole liver single cell
RNA sequencing and spatial transcriptomics reveals specific
cell sub-populations and pathways regulated by CCL24, Abstract
Identifier:
OS02
Presenter:
Raanan Greenman, PhD, Chemomab
Project Lead
Time:
June 23, 2022, 16:45 CET
Session:
Immune-mediated and cholestatic: Experimental and
pathophysiology
Information:
https://easl.eu/event/international-liver-congress-2022/
The presentation will be available at the R&D section of
Chemomab's website starting on June 24,
2022
In addition, Chemomab's business development team members will
be in San Diego, California
June 13-16, 2022, participating in
the BIO International Convention's One-on-One Partnering™
event. Registered attendees can click here to log in and
schedule a meeting with Chemomab.
About Chemomab Therapeutics
Ltd.
Chemomab is a clinical-stage biotechnology company focusing on
the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to begin in late 2022. For more information, visit
chemomab.com.
Contacts:
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 917-734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President,
Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-june-investor-and-scientific-conferences-301564848.html
SOURCE Chemomab Therapeutics, Ltd.